Hamed Shahbazi Purchases Niagen Bioscience Shares
On June 24, 2026, Hamed Shahbazi acquired 31,746 shares of Niagen Bioscience.
Key Points
- Hamed Shahbazi bought 31,746 shares of Niagen Bioscience on June 24, 2026, with the stock trading at $3.42.
- Niagen Bioscience has a market cap of $272.4 million, a P/E ratio of 16.3, and a 52-week range of $3.29 to $14.69.
- Analysts from HC Wainwright & Co. and Canaccord Genuity maintain a 'buy' rating with price targets between $10 and $23.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Hamed Shahbazi recently made a move to increase his stake in Niagen Bioscience, Inc. by purchasing 31,746 shares. The transaction took place on June 24, 2026, with the stock trading at $3.42 on the NasdaqCM.
Insider Buying and Selling at Niagen Bioscience, Inc.
On June 24, 2026, several insiders, including Hamed Shahbazi, bought 31,746 shares each of Niagen Bioscience. This series of purchases was not part of a pre-planned trading program. Other insiders involved in similar transactions on the same date included Frank Jaksch Jr, Gary Ng Wang Yu, Ann Cohen, Kristin Patrick, and Steven Rubin.
Other Institutional Activity in Niagen Bioscience
In recent institutional activity, BlackRock, Inc. reduced its holdings by 204,090 shares, bringing its total to 3,871,619 shares valued at approximately $17.1 million. Meanwhile, SteelPeak Wealth, LLC initiated a new position with 3,373,000 shares worth about $14.9 million. Arrowstreet Capital Limited Partnership increased its stake by 761,685 shares, reaching a total of 2,378,437 shares valued at $10.5 million. Vanguard Capital Management LLC also opened a new position with 2,149,277 shares, valued at $9.5 million. Tieton Capital Management, LLC added 384,062 shares for a total of 2,029,155 shares valued at $8.9 million. Qube Research & Technologies Ltd increased its holdings by 652,804 shares, totaling 1,714,639 shares worth $7.6 million.
Niagen Bioscience, Inc. Stock Up 4.0%
Shares of NasdaqCM:NAGE traded near $3.42 on Saturday. Niagen Bioscience has a market cap of approximately $272.4 million and a P/E ratio of 16.3. The stock's 52-week range is $3.29 to $14.69, with a 50-day moving average of $3.99 and a 200-day moving average of $5.83. The company has a current ratio of 4.61 and a quick ratio of 3.48, with a debt-to-equity ratio of 3.13.
$NAGE stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Niagen Bioscience reported revenue of $130.4 million, showing a modest growth of 3.3%. The company's net margin stands at 14.3%, with a return on equity of 27.1%. The next earnings report is expected on August 5, 2026.
Analysts Set New Price Targets
On May 11, 2026, HC Wainwright & Co. maintained a 'buy' rating for Niagen Bioscience with a price target of $11. Canaccord Genuity also maintained a 'buy' rating on May 5, 2026, with a target of $10. Overall, the consensus among analysts points to a 'buy' recommendation, with an average target price of $12.60 based on five analyst opinions.
About Niagen Bioscience
Niagen Bioscience, Inc. is a biotechnology company based in Los Angeles, California. It focuses on developing products aimed at promoting healthy aging. The company operates through various segments, including consumer products and pharmaceuticals. It is known for its flagship ingredient, nicotinamide riboside, marketed under the NIAGEN brand. The company distributes its products through online platforms like TRUNIAGEN.com and Amazon, as well as through specialty retailers and healthcare practitioners.
Bottom Line
Hamed Shahbazi's recent purchase of Niagen Bioscience shares is a notable insider transaction. Investors often track insider activity to gauge sentiment within a company. It's important to remember that insider transactions are disclosed after they occur, providing a historical perspective rather than a real-time indicator.
Get Niagen Bioscience, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NAGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.